[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 11749
1. Park EK, Jeon JS, Noh HJ, Won JH, Park HS: Complete remission of IgA nephropathy after bone marrow transplantation for acute myeloid leukaemia. NDT Plus; 2008 Dec;1(6):420-422

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of IgA nephropathy after bone marrow transplantation for acute myeloid leukaemia.
  • A 32-year-old woman was found to have IgA nephropathy and acute myeloid leukaemia.
  • We herein report a case of complete remission of IgA nephropathy after BMT for acute myeloid leukaemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Minerva Med. 2004 Oct;95(5):411-8 [15467516.001]
  • [Cites] Nat Med. 1998 Feb;4(2):153-5 [9461184.001]
  • [Cites] Kidney Int. 1996 Mar;49(3):839-45 [8648928.001]
  • [Cites] J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S2-6 [15938024.001]
  • [Cites] Exp Nephrol. 2002;10(1):51-8 [11803205.001]
  • [Cites] J Am Soc Nephrol. 2001 Jul;12(7):1401-9 [11423569.001]
  • [Cites] Kidney Int. 2007 Aug;72(3):319-27 [17495863.001]
  • [Cites] Clin Exp Nephrol. 2003 Sep;7(3):179-85 [14586713.001]
  • [Cites] N Engl J Med. 2002 Sep 5;347(10):738-48 [12213946.001]
  • (PMID = 28657023.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; IgA nephropathy / bone marrow transplantation
  •  go-up   go-down


2. Barrett AJ, Rezvani K: Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias. Clin Exp Immunol; 2007 May;148(2):189-98
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.
  • The graft-versus-leukaemia (GVL) effect following allogeneic stem cell transplantation is clear evidence that T lymphocytes can control and eliminate myeloid leukaemias.
  • The successful identification of a range of leukaemia specific antigens (LSA) in recent years has stimulated efforts to induce leukaemia specific T cell responses to these antigens with peptide vaccines.
  • An ideal LSA should be restricted in its expression to leukaemia including progenitor cells, intrinsically connected with the leukaemic phenotype, and capable of inducing strong cytotoxic T cell responses to the leukaemia.
  • Peptides from three well-characterized LSA, the breakpoint cluster region-abelson (BCR-ABL) fusion protein of chronic myelogenous leukaemia, proteinase-3 and Wilms tumour 1 protein, serve as the basis for several clinical trials using peptide and adjuvants to treat patients with a variety of myeloid malignancies.
  • Preliminary results from these studies indicate that these peptides induce immune responses which can translate into clinical responses which include complete remissions from leukaemia.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Leukemia, Myeloid / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4460-8 [15958631.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1315-23 [16219567.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1230-7 [16227990.001]
  • [Cites] Leukemia. 2006 Nov;20(11):2025-33 [16990779.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3865-70 [16902144.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4109-17 [16931630.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3786-92 [12893759.001]
  • [Cites] Cell. 2003 Oct 31;115(3):305-18 [14636558.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1037-42 [14504104.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1969-74 [14762166.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3076-83 [15070688.001]
  • [Cites] Cancer Immunol Immunother. 2002 Aug;51(6):299-310 [12111118.001]
  • [Cites] Exp Hematol. 2002 Jul;30(7):689-96 [12135665.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2132-7 [12200377.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5):494-502 [12407514.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3835-7 [12411326.001]
  • [Cites] Blood. 2003 Feb 1;101(3):1007-14 [12393606.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1752-8 [12393522.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1988-95 [12743153.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4485-91 [12576309.001]
  • [Cites] Transplantation. 2003 May 15;75(9):1429-36 [12792492.001]
  • [Cites] Leuk Res. 2003 Sep;27(9):795-802 [12804637.001]
  • [Cites] Leukemia. 2003 Jul;17(7):1301-12 [12835718.001]
  • [Cites] J Immunol. 2003 Aug 15;171(4):1780-91 [12902478.001]
  • [Cites] Expert Rev Vaccines. 2003 Jun;2(3):369-79 [12903802.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2892-900 [12829610.001]
  • [Cites] Nat Med. 2003 Nov;9(11):1377-82 [14528297.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):7043-52 [15501984.001]
  • [Cites] Br J Cancer. 1977 Mar;35(3):265-72 [322689.001]
  • [Cites] Nature. 1987 Jul 23-29;328(6128):342-4 [3474529.001]
  • [Cites] Cell. 1989 Dec 22;59(6):959-68 [2598267.001]
  • [Cites] J Exp Med. 1991 Jan 1;173(1):101-9 [1985117.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2462-5 [2265242.001]
  • [Cites] Clin Exp Immunol. 1991 May;84(2):232-7 [1851056.001]
  • [Cites] Immunol Today. 1991 Dec;12(12):443-6 [1786080.001]
  • [Cites] Immunogenetics. 1992;35(3):161-5 [1537607.001]
  • [Cites] Blood. 1993 Mar 1;81(5):1369-75 [8095167.001]
  • [Cites] Ann Rheum Dis. 1993 Feb;52(2):115-20 [8383482.001]
  • [Cites] Blood. 1993 Oct 15;82(8):2273-7 [8400279.001]
  • [Cites] Blood. 1993 Oct 15;82(8):2310-8 [8400284.001]
  • [Cites] EMBO J. 1994 Feb 15;13(4):764-73 [8112292.001]
  • [Cites] Clin Exp Immunol. 1994 Dec;98(3):448-53 [7994909.001]
  • [Cites] Br J Haematol. 1995 Feb;89(2):250-7 [7873374.001]
  • [Cites] J Leukoc Biol. 1995 Apr;57(4):543-7 [7722412.001]
  • [Cites] Clin Exp Immunol. 1995 May;100(2):186-93 [7743653.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):371-80 [15122208.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90 [15365188.001]
  • [Cites] Adv Pharmacol. 2004;51:255-70 [15464913.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):1014-21 [16338624.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8799-807 [16361568.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):34-42 [16397021.001]
  • [Cites] Leukemia. 2006 Feb;20(2):254-63 [16341043.001]
  • [Cites] J Exp Ther Oncol. 2006;5(3):183-93 [16528969.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):231-6 [16611662.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Jun;20(3):613-36 [16762727.001]
  • [Cites] Expert Rev Vaccines. 2006 Aug;5(4):467-72 [16989627.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1738-50 [16932347.001]
  • [Cites] Acta Haematol. 1999;102(2):72-6 [10529509.001]
  • [Cites] Blood. 2000 Jan 1;95(1):286-93 [10607714.001]
  • [Cites] Immunogenetics. 2000 Feb;51(2):99-107 [10663572.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1781-7 [10688838.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2198-203 [10733485.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1480-9 [10942395.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1018-23 [10973322.001]
  • [Cites] J Exp Med. 2001 Jan 1;193(1):73-88 [11136822.001]
  • [Cites] Blood. 2001 May 1;97(9):2764-71 [11313269.001]
  • [Cites] Blood. 2001 May 1;97(9):2903-7 [11313288.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):833-46 [11560998.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):871-80 [11697642.001]
  • [Cites] Blood. 2001 Nov 15;98(10):2887-93 [11698267.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3343-8 [11705846.001]
  • [Cites] J Virol. 2001 Dec;75(24):11983-91 [11711588.001]
  • [Cites] Methods Mol Med. 2002;68:223-37 [11901505.001]
  • [Cites] Blood. 2002 May 1;99(9):3272-9 [11964293.001]
  • [Cites] Leukemia. 1995 Jun;9(6):1060-7 [7596170.001]
  • [Cites] Blood. 1995 Sep 1;86(5):2041-50 [7655033.001]
  • [Cites] N Engl J Med. 1995 Oct 19;333(16):1038-44 [7675046.001]
  • [Cites] Clin Exp Immunol. 1996 Feb;103(2):253-8 [8565308.001]
  • [Cites] Blood. 1996 May 1;87(9):3587-92 [8611681.001]
  • [Cites] Leukemia. 1996 Apr;10(4):693-9 [8618449.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2878-84 [8639907.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):725-9 [8642276.001]
  • [Cites] Int Arch Allergy Immunol. 1996 Aug;110(4):299-307 [8768795.001]
  • [Cites] Am J Kidney Dis. 1996 Aug;28(2):178-85 [8768911.001]
  • [Cites] Curr Opin Immunol. 1996 Feb;8(1):75-81 [8729449.001]
  • [Cites] Blood. 1996 Sep 15;88(6):2118-24 [8822931.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2450-7 [8839835.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1133-42 [9028934.001]
  • [Cites] Immunol Today. 1997 Jun;18(6):267-8 [9190110.001]
  • [Cites] Blood. 1997 Jul 1;90(1):290-7 [9207464.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1217-25 [9242555.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2529-34 [9326217.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4938-46 [9389712.001]
  • [Cites] Blood. 1998 Feb 1;91(3):977-83 [9446659.001]
  • [Cites] J Clin Invest. 1998 May 15;101(10):2290-6 [9593785.001]
  • [Cites] J Immunother. 1999 Jan;22(1):1-6 [9924693.001]
  • [Cites] Curr Opin Immunol. 1999 Feb;11(1):82-8 [10047538.001]
  • [Cites] Annu Rev Immunol. 1999;17:51-88 [10358753.001]
  • [Cites] Immunity. 1999 Jun;10(6):673-9 [10403642.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1038-45 [10419896.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1201-8 [10438707.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2487-96 [10498622.001]
  • [Cites] Blood. 2005 Jan 15;105(2):865-73 [15280205.001]
  • [Cites] Leukemia. 2005 Feb;19(2):268-74 [15538407.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):657-62 [15721470.001]
  • [Cites] J Intern Med. 2005 Apr;257(4):319-28 [15788001.001]
  • [Cites] Br J Haematol. 2005 May;129(3):340-9 [15842657.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):8210-8 [15944330.001]
  • (PMID = 17437417.001).
  • [ISSN] 0009-9104
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Peptide Fragments; 0 / WT1 Proteins; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 113
  • [Other-IDs] NLM/ PMC1868869
  •  go-up   go-down


3. Cony-Makhoul P, Bergeron A, Corm S, Dubruille V, Rea D, Rigal-Huguet F, Nicolini FE: [Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias]. Bull Cancer; 2008 Sep;95(9):805-11
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
  • [Transliterated title] Recommandations pour la gestion des effets indésirables du traitement par dasatinib (Sprycel) au cours de la leucémie myéloïde chronique et des leucémies aiguës lymphoblastiques à chromosome Philadelphie.
  • Dasatinib (Sprycel) is a new-targeted therapy used since 2005 in the treatment of chronic myelogenous leukemia and de novo Philadelphia positive acute lymphoblastic leukaemia patients, intolerant or resistant to imatinib.
  • Recently, dasatinib dose optimisation in chronic-phase has reduced the incidence of such adverse events without modification of the efficacy, however, their optimal overall management can efficiently reduce their severity and minimize their impact on disease response.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / adverse effects. Thiazoles / adverse effects
  • [MeSH-minor] Benzamides. Bone Marrow / drug effects. Bone Marrow Diseases / chemically induced. Dasatinib. Drug Resistance, Neoplasm. Female. France. Humans. Imatinib Mesylate. Male. Piperazines / therapeutic use. Pleural Effusion / chemically induced. Pregnancy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829412.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Practice Guideline
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; RBZ1571X5H / Dasatinib
  •  go-up   go-down


Advertisement
4. Lukina EA, Sysoeva EP, Kitsenko EA, Varlamova EIu, Inozemtseva MV, Semenova EA, Nadinskaia MIu, Ivashkin VT: [Syndrome of extrahepatic portal hypertension and chronic abdominal ischemia in patient with subleukemic myelosis and congenital immunodeficiency]. Ter Arkh; 2009;81(7):82-4
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Syndrome of extrahepatic portal hypertension and chronic abdominal ischemia in patient with subleukemic myelosis and congenital immunodeficiency].
  • The article demonstrates objective difficulties and subjective mistakes in assessment of a clinical picture in a patient with subleukemic myelosis and thrombosis of the portal system.
  • [MeSH-major] Abdomen / blood supply. Hypertension, Portal / diagnosis. IgA Deficiency / diagnosis. Ischemia / diagnosis. Primary Myelofibrosis / diagnosis
  • [MeSH-minor] Adult. Anticoagulants / administration & dosage. Anticoagulants / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Chronic Disease. Female. Humans. Hydroxyurea / administration & dosage. Hydroxyurea / therapeutic use. Syndrome. Treatment Outcome. Venous Thrombosis / complications. Venous Thrombosis / diagnosis. Venous Thrombosis / drug therapy

  • Genetic Alliance. consumer health - Portal hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708581.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


5. Oliansky DM, Appelbaum F, Cassileth PA, Keating A, Kerr J, Nieto Y, Stewart S, Stone RM, Tallman MS, McCarthy PL Jr, Hahn T: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant; 2008 Feb;14(2):137-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review.
  • Clinical research examining the role of hematopoietic stem cell transplantation (HSCT) in the therapy of acute myelogenous leukemia (AML) in adults is presented and critically evaluated in this systematic evidence-based review.
  • Treatment recommendations based on the evidence are presented in Table 3, entitled Summary of Treatment Recommendations Made by the Expert Panel for Adult Acute Myelogenous Leukemia, and were reached unanimously by a panel of AML experts.
  • (4) What is the impact on survival outcomes of unrelated donor HSCT vesus chemotherapy in younger (<40 years) adults with high risk disease?
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy


6. Weight is a risk factor for treatment mortality in AML. Nurs Stand; 2005 Feb 16;19(23):10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Underweight or overweight children with acute myeloid leukaemia (AML) are more likely to succumb to treatment-related complications than their normal weight counterparts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28091019.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. el-Shami K, Smith BD: Immunotherapy for myeloid leukemias: current status and future directions. Leukemia; 2008 Sep;22(9):1658-64

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy for myeloid leukemias: current status and future directions.
  • Myeloid leukemias, although a heterogeneous group of hematopoietic stem cell neoplasms, are arguably among the most suited for active specific immunotherapy.
  • Nevertheless, clinical development of myeloid leukemia vaccine lagged behind similar approaches in other solid and hematological malignancies.
  • The recent identification of apparently specific leukemia antigens and advances in understanding the fundamentals of tumor immunology have helped initiate a number of early phase clinical studies evaluating the safety and clinical efficacy of this approach.
  • Here we review the recently identified and characterized putative leukemia antigens, the main vaccination strategies employed by most investigators and the results of clinical studies of immunotherapy of myeloid leukemias.
  • Although these studies are early and often difficult to interpret, they offer evidence that effective immunity to leukemia could be induced following vaccination, and that clinical benefit can sometimes be observed, thus setting the stage for future development of this strategy and in the combinatorial approaches to treatment of myeloid leukemias that incorporate immunotherapy.
  • [MeSH-major] Immunotherapy / methods. Leukemia, Myeloid / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18563174.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines
  • [Number-of-references] 60
  • [Other-IDs] NLM/ NIHMS281188; NLM/ PMC4764877
  •  go-up   go-down


8. Dao T, Scheinberg DA: Peptide vaccines for myeloid leukaemias. Best Pract Res Clin Haematol; 2008 Sep;21(3):391-404
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peptide vaccines for myeloid leukaemias.
  • The development of cancer vaccines directed against myeloid leukaemias has been a research area of intense interest in the past decade.
  • Both human studies in vitro and mouse models in vivo have demonstrated that leukaemia-associated antigens (LAAs), such as the fusion protein BCR-ABL, Wilms' tumour protein and proteinase 3, may serve as effective targets for cellular immunotherapy.
  • Peptide-based vaccines are able to induce cytotoxic T-lymphocyte responses that kill leukaemia cells.
  • Based on these results, pilot clinical trials have been initiated in chronic and acute myeloid leukaemia and other haematological malignancies, which include vaccination of patients with synthetic peptides derived from these LAAs.
  • This chapter will focus mainly on discussing the preclinical studies of peptide vaccines in human systems, the results from clinical trials and the future prospects for vaccine therapy for myeloid leukaemia.
  • [MeSH-major] Leukemia, Myeloid / immunology. Vaccines, Subunit / therapeutic use
  • [MeSH-minor] CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Fusion Proteins, bcr-abl / immunology. Humans. Immunotherapy / methods. Kidney Neoplasms / immunology. Kidney Neoplasms / therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology. Myeloblastin / immunology. Neoplasm Proteins / immunology. WT1 Proteins / immunology. Wilms Tumor / immunology. Wilms Tumor / therapy

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790445.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Vaccines, Subunit; 0 / WT1 Proteins; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.4.21.76 / Myeloblastin
  • [Number-of-references] 86
  •  go-up   go-down


9. Hauck FH, Tanner SM, Henker J, Laass MW: Imerslund-Gräsbeck syndrome in a 15-year-old German girl caused by compound heterozygous mutations in CUBN. Eur J Pediatr; 2008 Jun;167(6):671-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imerslund-Gräsbeck syndrome (IGS) is a recessive disorder of intestinal cobalamin (Cbl) absorption and renal tubular protein reabsorption sometimes accompanied by urinary tract malformation.
  • We report the case of a 15-year-old German girl who presented with megaloblastic anaemia and funicular myelosis due to Cbl-deficiency and selective proteinuria.
  • In conclusion IGS should be considered in paediatric patients presenting with symptoms like megaloblastic anaemia, funicular myelosis and benign proteinuria.
  • Diagnosis should be confirmed genetically to avoid further invasive diagnostics, administer proper lifelong treatment and offer genetic counselling.

  • Genetic Alliance. consumer health - German Syndrome.
  • Genetic Alliance. consumer health - Megaloblastic anemia.
  • MedlinePlus Health Information. consumer health - Malabsorption Syndromes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17668238.001).
  • [ISSN] 0340-6199
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / intrinsic factor-cobalamin receptor
  •  go-up   go-down


10. Rasaiyaah J, Yong K, Katz DR, Kellam P, Chain BM: Dendritic cells and myeloid leukaemias: plasticity and commitment in cell differentiation. Br J Haematol; 2007 Aug;138(3):281-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cells and myeloid leukaemias: plasticity and commitment in cell differentiation.
  • This review examines the relationship between the acute and chronic myeloid leukaemias and cells with DC properties.
  • DCs are non-dividing terminally differentiated cells, and ex vivo leukaemic cells or cell lines show little similarity to DCs.
  • However, many leukaemias differentiate further in response to defined stimuli, and retain a degree of lineage plasticity.
  • Recent data suggest that the most 'dendritic-like' cells can be derived from more undifferentiated myeloid leukaemias, such as the myelomonocytic Mutz-3 cell line.
  • [MeSH-major] Dendritic Cells / pathology. Leukemia, Myeloid / pathology
  • [MeSH-minor] Acute Disease. Cell Differentiation. Cell Line, Tumor. Cell Lineage. Chronic Disease. Humans. Immunity, Innate. Immunotherapy, Adoptive

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614817.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 66
  •  go-up   go-down


11. Maka E, Lukáts O, Tóth J, Fekete S: Orbital tumour as initial manifestation of acute myeloid leukemia: granulocytic sarcoma: case report. Pathol Oncol Res; 2008 Jun;14(2):209-11
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital tumour as initial manifestation of acute myeloid leukemia: granulocytic sarcoma: case report.
  • We report orbital involvement as an initial manifestation of acute myeloid leukemia in a 57-year-old woman.
  • Orbital biopsy was performed on the right side; and histopathology disclosed a myelocytic tumour.
  • There appear to be only a few previous reports of acute myeloid leukemia cases presenting with orbital involvement, and most cases occurred in children.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Orbital Neoplasms / diagnosis. Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Acute Disease. Diagnosis, Differential. Exophthalmos / etiology. Fatal Outcome. Female. Humans. Immunohistochemistry. Middle Aged. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18431695.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


12. Sokolova MA, Khoroshko ND, Tsvetaeva NV, Turkina AG, Levina AA, Mamukova IuI, Rokhnianskaia AA, Sudarikov AB, Romanova EA, Vasil'ev SA, Sukhanova GA, Orel EB, Rudakova VE, Tutaeva VV, Manakova TE, Semenova EA, Kulikov SM: [Hyperhomocysteinemia--one of the factors underlying thrombotic complications in patients with chronic myeloproliferative diseases]. Ter Arkh; 2007;79(12):57-62
MedlinePlus Health Information. consumer health - Blood Clots.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hyperhomocysteinemia--one of the factors underlying thrombotic complications in patients with chronic myeloproliferative diseases].
  • AIM: To assess incidence of hyperhomocysteinemia (HHC) in patients with chronic myeloproliferative diseases (CMPD) and to analyse possible correlation between an elevated concentration of plasma homocystein (HC) and thrombotic complications.
  • The highest HC was in patients with subleukemic myelosis (SLM)--23 +/- 2.3 mcmol).
  • [MeSH-minor] Adolescent. Adult. Biomarkers / blood. Chronic Disease. DNA / genetics. Female. Follow-Up Studies. Humans. Incidence. Male. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Middle Aged. Platelet Count. Point Mutation. Polymerase Chain Reaction. Prognosis. Prothrombin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18220034.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers; 0 / factor V Leiden; 0LVT1QZ0BA / Homocysteine; 9001-24-5 / Factor V; 9001-26-7 / Prothrombin; 9007-49-2 / DNA; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


13. Tan S, Wang G, Peng M, Zhang X, Shen G, Jiang J, Chen F: Detection of myeloperoxidase activity in primary leukemic cells by an enhanced chemiluminescent assay for differentiation between acute lymphoblastic and non-lymphoblastic leukemia. Clin Chim Acta; 2009 May;403(1-2):216-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of myeloperoxidase activity in primary leukemic cells by an enhanced chemiluminescent assay for differentiation between acute lymphoblastic and non-lymphoblastic leukemia.
  • BACKGROUND: Myeloperoxidase (MPO) plays a crucial role in the differentiation of acute lymphoblastic leukemia (ALL) and acute non-lymphoblastic leukemia (ANLL).
  • In this report, we proposed the application of the enhanced chemiluminescent (ECL) technique to the determination of MPO activity in blasts of acute leukemia (AL).
  • [MeSH-major] Leukemia, Myeloid, Acute / enzymology. Leukemia, Myeloid, Acute / pathology. Luminescent Measurements / methods. Peroxidase / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Diagnosis, Differential. Female. HL-60 Cells. Humans. Infant. Male. Middle Aged

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Non Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19298796.001).
  • [ISSN] 1873-3492
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


14. Tretiak NM, Vakul'chuk OM, Kalinina SIu: [Induced acute non-lymphoblastic leukemia and prognostic significance of cytogenetic abnormalities: trisomy in chromosome 8, inv(16)(p13q22), and t(8;21)(q22;q22)]. Lik Sprava; 2008 Jan-Feb;(1-2):89-96
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induced acute non-lymphoblastic leukemia and prognostic significance of cytogenetic abnormalities: trisomy in chromosome 8, inv(16)(p13q22), and t(8;21)(q22;q22)].
  • 3 patients with secondary acute non-lymphoblastic leucosis have been observed.


15. Le Coutre PD, Giles F, Hochhaus A, Apperley JF, Ossenkoppele G, Haque A, Gallagher NJ, Baccarani M, Cortes J, Kantarjian H: Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):7057

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study.
  • Grade 3/4 non-hematologic AEs were rare (< 1%) and included nausea, fatigue, and diarrhea.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961447.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Bloomfield CD: Importance of genetic heterogeneity in curing adult acute leukemia (AL). J Clin Oncol; 2009 May 20;27(15_suppl):s1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of genetic heterogeneity in curing adult acute leukemia (AL).
  • Publication of the French-American-British classification 34 years ago resulted in acceptance that morphology and cytochemistry separated AL into two different diseases, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), that required separate treatment.
  • During the next 15-20 years the importance of cytogenetics in dissecting ALL and AML into entities requiring different therapies became widely accepted, resulting in 2001 in their first incorporation into the World Health Organization (WHO) classification of AL.
  • The most striking example of increased curability of AL is acute promyelocytic leukemia, in which targeted therapy combined with chemotherapy has increased survival from a 2-week median to an 80% cure rate.
  • Recognition of increased sensitivity of a genetic subtype of AML to high-dose cytarabine (HiDAC) has increased the cure rate of core-binding factor (CBF) AML from <10%-25% to 55%-60%.
  • Among adult de novo AML 40%-45% are cytogenetically normal (CN); the striking molecular heterogeneity of CN-AML is now being recognized and promises to allow individualized approaches that improve substantially upon the current cure rate of 40%.
  • New approaches to studying the leukemia genome and epigenome should improve our understanding of AL heterogeneity, identify new therapeutic targets, and allow the cure of most patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962366.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Becker H, Marcucci G, Maharry K, Margeson D, Radmacher MD, Whitman SP, Mrózek K, Baer MR, Larson RA, Bloomfield CD, for Cancer and Leukemia Group B (CALGB): NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML). J Clin Oncol; 2009 May 20;27(15_suppl):7000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML).
  • METHODS: Pretreatment marrow was studied in 189 older CN AML pts [median age 69 y (60 - 83 y); 162 de novo & 27 secondary (s; prior hematologic disorders) cases] enrolled on CALGB 9720 (n=106) & 10201 (n=83).
  • RESULTS: In de novo CN AML, NPM1 mutated (NPM1mut) pts (54%) had more CRs (85% v 45%, P<.0001) & longer relapse-free (RFS) (P=.02; 3 y rates 23% v 10%) & overall survival (OS) (P<.0001; 3 y 34% v 7%) than NPM1 wild-type (NPM1wt) pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963957.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Prabhash K, Vora T, Ghadyalpatil NS, Rangarajan B, Hingmire SS, Menon H, Jain P, Kurkure PA, Parikh PM: Patterns of imatinib resistance mutation analysis in chronic myeloid leukemia (CML) patients on imatinib at the time of loss of response to the drug in Asian Indian subjects. J Clin Oncol; 2009 May 20;27(15_suppl):7079

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of imatinib resistance mutation analysis in chronic myeloid leukemia (CML) patients on imatinib at the time of loss of response to the drug in Asian Indian subjects.
  • RESULTS: This group included 22 patients with chronic phase (CP) disease, 2 patients with accelerated phase (AP), and 1 patient with extramedullary blast crisis (BC).
  • Fourteen patients received treatment with agents other than imatinib as the first-line therapy due to either nonavailability of the drug at the time of diagnosis in India, but were started on imatinib when drug became available.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961486.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Rangarajan B, Prabhash K, Nair R, Menon H, Jain P, Kannan S, Jeevangi NK, Bagal B, Parikh PM, Kurkure PA: Rater. J Clin Oncol; 2009 May 20;27(15_suppl):e20678

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inclusion criteria were diagnosis of hematolymphoid malignancy, neutropenic febrile episode secondary to chemotherapy or during induction therapy of acute leukemia and more than 18 years of age All patients were risk stratified, hospitalized and treated with broad-spectrum, empiric, intravenous antibiotic therapy until recovery or outcome of the event.
  • We subsequently analyzed the subset of Acute Myeloid Leukemia (AML) patients as they were the majority comprising of 62/81 episodes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961676.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Tsai DE, Wang W, Reshef R, Vogl D, Stadtmauer E, Andreadis C, Carlson A, Luger S: Effect of bexarotene on platelet counts in patients undergoing cancer treatment: An analysis of clinical trials in lung cancer and leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):e20533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of bexarotene on platelet counts in patients undergoing cancer treatment: An analysis of clinical trials in lung cancer and leukemia.
  • In patients receiving this agent for acute myeloid leukemia (AML), we noted increases in platelet counts.
  • METHODS: We analyzed platelet count data from 3 Bex clinical trials encompassing non-small cell lung cancer (NSCLC) and AML.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960979.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Yeh C, Ma W, Kantarjian H, Zhang ZJ, Cortes J, Albitar M: BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. J Clin Oncol; 2009 May 20;27(15_suppl):7028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7028 Background: The major mechanism underlying imatinib resistance in patients with chronic myeloid leukemia (CML) is clonal expansion of leukemic cells with point mutations in the BCR-ABL tyrosine kinase.
  • We describe three novel ABL premature termination mutations leading to BCR-ABL truncation in leukemia patients with multidrug (imatinib/nilotinib/dasatinib) resistance.
  • Total nucleic acids were purified and subjected to two rounds of PCR analysis, with the first PCR designed to eliminate amplification of the wild-type, non-translocated ABL gene.
  • HL60 cells (a Ph-negative myeloid leukemia cell line) and peripheral blood of healthy subjects were used as negative controls; a human CML cell line (K562) was used as a positive control.
  • RESULTS: We identified an exon 7 deletion in three CML patients, a 4-nt insertion (908insCAGG) near the exon 5/6 junction in one CML case, and an exon 6 point mutation (997C>T) in one patient with acute lymphoblastic leukemia (ALL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961401.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gupta N, Diderichsen PM, Steinberg J, Ricker JL, Humerickhouse R, Awni W, Pradhan R: Population pharmacokinetic (PK) analysis of ABT-869 in solid tumors and acute myelogenous leukemia (AML) patients. J Clin Oncol; 2009 May 20;27(15_suppl):3567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population pharmacokinetic (PK) analysis of ABT-869 in solid tumors and acute myelogenous leukemia (AML) patients.
  • The objectives of this analysis were to understand the population pharmacokinetics of ABT-869 and explore the effect of several demographic/disease state covariates influencing ABT-869 disposition.
  • METHODS: A population PK analysis of 181 patients (pts) enrolled in two phase 1 (multiple types of solid tumors and AML) and three phase 2 monotherapy studies (non-small cell lung cancer, hepatocellular carcinoma [HCC] and renal cell carcinoma) was conducted.
  • Available plasma concentrations obtained after intensive and sparse pre-dose PK sampling were analyzed by population PK using the non linear mixed effects modeling (NONMEM) approach.
  • Potential covariates including body weight, body surface area (BSA), age, sex, creatinine clearance (CrCL) and disease state (HCC vs. non-HCC pts) were tested.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961681.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Arellano ML, Winton E, Pan L, Souza L, Sunay S, Lima L, McLemore M, Heffner LT, Langston A, Khoury HJ: Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7070

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML).
  • : 7070 Background: In contrast to the poor prognosis associated with hyperleukocytosis, the prognostic significance of leukopenia at the time of diagnosis of AML is unknown.
  • RESULTS: Patients' characteristics (gender, secondary vs. de novo, and cytogenetic [CTG] risk) were comparable between the 2 groups.
  • Induction mortality was 0% for leukopenic and 5% for non-leukopenic pts.
  • In primary refractory pts, median survival was longer for leukopenic (11) vs. non-leukopenic (34) pts: 137 vs. 81 d (p = 0.026).
  • Event-free (EFS), disease-free (DFS), and overall survivals (OS) were lower in the leukopenic group: 12 vs. 14; 14 vs. 17; and 17 vs. 19 mos, respectively; but did not reach statistical significance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961453.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Santos FP, Qiao W, Cortes JE, Jones D, Ravandi F, Verma D, Kantarjian H, Borthakur G: Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (AML).
  • A Cox model was fit for OS, and non-significant variables were eliminated in a step-down fashion with a p- value cut-off of p = .10.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961388.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. McHayleh WM, Redner R, Sehgal R, Raptis A, Agha M, Natale J, Luong T, Schlesselman JJ, Foon K, Boyiadzis M: Etoposide and mitoxantrone in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy with cytarabine and idarubicin. J Clin Oncol; 2009 May 20;27(15_suppl):7073

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etoposide and mitoxantrone in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy with cytarabine and idarubicin.
  • : 7073 Background: The goal of induction chemotherapy in acute myeloid leukemia (AML) is complete remission with restoration of normal bone marrow.
  • If residual leukemia is present after the first course of induction therapy, patients receive a second course identical to the first or receive a non-cross resistant antileukemic regimen.
  • Lower CR rate was associated with unfavorable cytogenetic risk status at diagnosis and higher percent blasts prior to treatment with mitoxantrone and etoposide.
  • CONCLUSIONS: Our study suggests that the combination of etoposide and mitoxantorne is an active and well-tolerated regimen as second-course therapy in newly diagnosed AML patients who have persistent leukemia after a first course of induction therapy with cytarabine and idarubicin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961456.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Rao AV, Valk P, Metzeler KH, Acharya C, Rizzieri DA, Delwel R, Bohlander SH, Buske C, Potti A, Lowenberg B: Age-specific differences in oncogenic pathway deregulation and chemosensitivity in patients with acute myeloid leukemia: Strategies to maximize response to induction chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):7013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-specific differences in oncogenic pathway deregulation and chemosensitivity in patients with acute myeloid leukemia: Strategies to maximize response to induction chemotherapy.
  • : 7013 Background: Despite all the advances made in understanding the poor prognosis of acute myeloid leukemia (AML) in the elderly, the underlying biology at a molecular signaling pathway level has yet to be defined.
  • Standard Kaplan-Meier survival curves were generated using the two-sided log-rank test and individual differences in the probability of oncogenic pathway deregulation between young vs. elderly were analyzed via the non-parametric Mann-Whitney U test and a one-sided p-value ≤ 0.05 was considered statistically significant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961386.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Schwind S, Marcucci G, Maharry K, Radmacher MD, Whitman SP, Paschka P, Mrózek K, Kolitz JE, Larson RA, Bloomfield CD, Cancer and Leukemia Group B (CALGB): MicroRNA 181a (miR-181a) expression as a prognosticator in cytogenetically normal acute myeloid leukemia (CN AML). J Clin Oncol; 2009 May 20;27(15_suppl):7001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA 181a (miR-181a) expression as a prognosticator in cytogenetically normal acute myeloid leukemia (CN AML).
  • METHODS: We analyzed 187 de novo CN AML adult patients (pts) aged <60 years (y; median 45) similarly treated on CALGB 9621 and 19808.
  • The mean of 2 miR-181a probe log intensities was used as a continuous variable for analyses.
  • RESULTS: Higher miR-181a levels (miR-181a↑) were associated with CEBPA mut, NPM1 wt, no FLT3-TKD, lower ERG expression, higher %FAB M1/M2, lower WBC and age, higher blood blasts, and lower % gum hypertrophy. miR-181a↑ tended to associate with more complete remissions (CRs; p = .07) and significantly associated with longer disease-free (DFS; p = .05) and overall (OS; p = .01) survival (median follow-up 6.5 y for pts alive).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961373.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Rubnitz J, Inaba H, Ribeiro R, Pounds S, Pui C, Leung W: Pilot study of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):10034

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
  • : 10034 Background: In the setting of hematopoietic stem cell transplantation (HSCT), donor natural killer (NK) cells exhibit potent anti-leukemic effects without causing graft-versus-host disease.
  • We hypothesized that the transplantation of purified haploidentical NK cells may be a safe and effective form of consolidation therapy that will reduce the risk of relapse among children with acute myeloid leukemia (AML) who are not treated with HSCT.
  • RESULTS: The 10 patients had a median age of 2.5 years (range, 8 months to 21 years) and a median leukocyte count of 62 x 10<sup>9</sup>/L (range, 4 to 487) at diagnosis.
  • Leukemic cell genetic abnormalities included CBFβ-MYH11in 4 cases, RBM15-MKL1in 2 cases, MLL-ENL and MLL-AF9 in 1 case each; 2 cases had no detectable abnormalities.
  • One patient had prolonged NK engraftment (189 days), but no non-hematological toxicity.
  • Grade 3-4 non-hematological toxicity was limited to one respiratory viral infection and one episode of febrile neutropenia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962581.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Guérin A, Guo A, Williams D, Yu AP, Wu E, Latremouille-Viau D, Tsaneva M, Signorovitch J, Griffin JD: Treatment patterns of chronic myelogenous leukemia patients with suboptimal responses to imatinib. J Clin Oncol; 2009 May 20;27(15_suppl):7090

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment patterns of chronic myelogenous leukemia patients with suboptimal responses to imatinib.
  • : 7090 Background: Imatinib is the first-line therapy for Philadelphia chromosome-positive chronic myelogenous leukemia (CML).
  • METHODS: Two large U.S. administrative claims databases from January 1999 to March 2008 were combined (MarketScan and Ingenix Impact) to extract de-identified information of patients diagnosed with CML (ICD-9 code: 205.1) who were initiated on imatinib.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961257.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Plunkett W, Thomas DA, O'Brien SM, Federl S, Giles FJ, Nicol SJ, Gill J, Zhao L, Ravandi F, Kantarjian H: Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):7068

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia.
  • The purpose of this phase I trial was to define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of pemetrexed given with vitamin supplementation to patients with relapsed or refractory leukemia.
  • METHODS: Patients ≥15 years of age were enrolled with relapsed or refractory leukemia, Eastern Cooperative Oncology Group performance status ≤2, adequate renal and hepatic function, and life expectancy of ≥6 weeks.
  • RESULTS: Twenty-two patients entered the trial; median age was 50 years (range: 18-75); 15 patients had acute myeloid leukemia and 7 patients had acute lymphocytic leukemia (ALL).
  • Two patients died during the study due to disease progression and 1 patient discontinued due to a subdural hematoma of unknown cause.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961463.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta EM, Dewald G, Ketterling RP, Rowe JM, Lazarus HM, Tallman MS: A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900. J Clin Oncol; 2009 May 20;27(15_suppl):7003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900.
  • : 7003 Background: In younger adults with newly diagnosed acute myeloid leukemia (AML), anthracycline dose intensification during induction may improve complete remission (CR) rates; however, an improvement in overall survival (OS) in a randomized trial has not been demonstrated.
  • There were no differences in patient demographics or disease characteristics between the two groups at presentation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961375.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Medeiros BC, Gotlib JR, Coutre SE, Jones C, Khan SA, Rajwanshi R, Rajwanshi R, Zehnder J, Zehnder J: Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):7052

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia.
  • : 7052 Background: High treatment-related mortality and low response rates often discourage elderly patients with acute myeloid leukemia from receiving treatment.
  • Previous data demonstrate that only patients lacking expression of O6-alkylguanine-DNA alkyltransferase (AGAT) in leukemic blasts are sensitive to temozolomide.
  • De novo AML was diagnosed in eight patients and five patients had s-AML.
  • Drug-related hematologic toxicities were difficult to distinguish from disease-related cytopenias.
  • Seven patients have died from disease progression, while two patients died of neutropenic sepsis (early deaths).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961417.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Pigazzi M, Manara E, Baron E, Beghin A, Basso G: The inducible cyclic adenosine 3',5'-monophosphate early repressor (ICER) enhances drug sensitivity in acute myeloid leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):e22045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The inducible cyclic adenosine 3',5'-monophosphate early repressor (ICER) enhances drug sensitivity in acute myeloid leukemia.
  • CREB was previously demonstrated to be overexpressed in acute leukemia, whereas ICER was found rapidly degradated being unable to control gene transcription.
  • ICER exogenous expression was demonstrated to repress CREB targets preventing leukemia progression.
  • We hypothesized that ICER restoration deserves a special consideration for playing a role in CREB oncogenic feature and in modeling leukemic cell phenotype.
  • We monitored transcription and translation of a series of genes involved in different pathways by quantitative gene expression and western blot analysis.
  • RESULTS: We revealed that ICER was able to control gene expression in leukemia, principally of genes involved in cell death and survival.
  • The ability of ICER to modify leukemic cells phenotype respect to chemotherapeutic treatment gave an important information for targets and therapeutic possibilities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963227.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Laille E, Ward R, Nasser A, Stoltz M, Cogle C, Gore S, Skikne BS, Garcia-Manero G: The pharmacokinetics of azacitidine following subcutaneous treatment in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7087

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pharmacokinetics of azacitidine following subcutaneous treatment in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961481.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Pemmaraju N, Kantarjian H, Ravandi F, O'Brien S, Wierda W, Thomas D, Garcia-Manero G, Borthakur G, Pierce S, Cortes J: Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience. J Clin Oncol; 2009 May 20;27(15_suppl):7051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience.
  • : 7051 Background: AML is a heterogeneous group of hematopoietic neoplasms demonstrating clonal proliferation of myeloid precursors and is typically a disease of older adults.
  • This cohort included 27 (17%) pts with Core Binding Factor (CBF)-AML [inv(16), t(8:21)] and 19 pts (12%) with acute promyelocytic leukemia (APL).
  • Outcome is better for pts with CBF leukemia (3 yr survival 56%, sustained CR 49%) and APL (3 yr survival 51%, sustained CR 36%) compared to other AML (3 yr survival 28%, sustained CR 24%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961415.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA: A phase I trial of adoptive transfer of allogeneic natural killer (NK) cells in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):3001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of adoptive transfer of allogeneic natural killer (NK) cells in patients (pts) with advanced non-small cell lung cancer (NSCLC).
  • : 3001 Background: HLA-mismatched NK cells have been found effective in acute myeloid leukemia pts.
  • RESULTS: Between 11/2007 and 11/2008 16 pts (performance status 0-1) were enrolled; 1 pt had rapid disease progression before treatment.
  • With a median follow-up of 6 months (range, 1-14) 3 pts with partial response and 7 pts with disease stabilization were recorded.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962051.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Ritchie EK, Roboz G, Hinchcliff K, Curcio T, Scandura J, Feldman E: Phase I trial of laromustine in combination with infusional ara-C in elderly patients over age 60 with newly diagnosed AML or high-grade MDS. J Clin Oncol; 2009 May 20;27(15_suppl):7054

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7054 Background: Laromustine is a novel sulfonylhydrazine-alkylating agent with activity in acute myeloid leukemia (AML).
  • Laromustine in phase I and II trials shows activity in patients with relapsed/refractory leukemia (1) and elderly patients with new AML (2).
  • Patients achieving CR after induction therapy were offered up to 2 cycles of consolidation therapy for a maximum cumulative laromustine dose of 1,000 mg/m2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961420.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Flinn IW, Byrd JC, Furman RR, Brown JR, Lin TS, Bello C, Giese NA, Yu AS: Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):3543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro studies of 0.1 to 10 μM CAL-101 showed inhibition of pAKT expression and/or apoptotic effects against primary chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) cells and against a range of leukemia and lymphoma cell lines.
  • METHODS: In an ongoing phase 1 dose escalation study in sequential cohorts of 3 patients with relapsed/refractory CLL or select B-cell non-Hodgkin's lymphoma, CAL-101 is administered orally twice daily for 28 days per cycle.
  • Two of 6 patients attained partial response and 4 have stable disease.
  • Disease specific cohort expansion will occur at the maximally tolerated dose, and patients with AML will be added.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961357.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Ghavamzadeh A, Hashemi S, Alimoghaddam K, Nasri Moghaddam Z, Shadpour M, Jalili M: Phase II trial of old age acute myeloid leukemia treatment by arsenic trioxide and low-dose subcutaneous cytosin arabinoside. J Clin Oncol; 2009 May 20;27(15_suppl):7075

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of old age acute myeloid leukemia treatment by arsenic trioxide and low-dose subcutaneous cytosin arabinoside.
  • : 7075 Background: AML is a disease of old age, but unfortunately due to several factors standard treatment can not be delivered to these patients.
  • Complete remission observed in 6 and partial remission in one patient (RR = 63.6%), but remission was short live, after 6 months one patient was in CR and one in PR.
  • After 12 months, only one patient was in PR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961458.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Verma D, Kantarjian H, Jones D, Borthakur G, Garcia-Manero G, Thomas DA, Verstovsek S, Rios M, Cortes J: Chronic myeloid leukemia (CML) with e1a2 BCR-ABL fusion transcript type: Analysis of characteristics, outcomes, and prognostic significance. J Clin Oncol; 2009 May 20;27(15_suppl):7030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic myeloid leukemia (CML) with e1a2 BCR-ABL fusion transcript type: Analysis of characteristics, outcomes, and prognostic significance.
  • Median age at diagnosis was 60 (range 28-86) years, median follow-up 39.5 (range 2-109) months.
  • 5 patients (2 post-interferon failure - 1 in CHR, 1 in PCyR; 3 frontline imatinib - 1 in CHR, 1 in CCyR, 1 non-responder) progressed to advanced phases (3 myeloid BP, 1 lymphoid BP, 1 AP) at a median 48 (range 4-92) months after CML diagnosis; with only 1 alive and in CMR after allogeneic SCT.
  • Six patients (5 CP, 1 AP) were alive at a median 39 (range 2-85) months after initial diagnosis: 4 with CHR (2 on imatinib, 1 nilotinib, 1 bosutinib), 1 with MCyR on imatinib, and 1 with CMR after allogeneic SCT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961392.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Marcucci G, Maharry K, Whitman SP, Paschka P, Baldus CD, Langer C, Mrózek K, Kolitz JE, Larson RA, Bloomfield CD, Cancer and Leukemia Group B (CALGB): Improving the molecular risk classification for younger (&lt;60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts). J Clin Oncol; 2009 May 20;27(15_suppl):7002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts).
  • : 7002 Background: CN AML pts are currently stratified into Low-risk [FLT3-ITD negative (neg)/NPM1 mutated (mut)] and High-risk [FLT3-ITD positive (pos) or NPM1 wild type (wt)] groups (FLT3-ITD/NPM1-only classification).
  • Here, we assess if adding CEBPA and WT1 mutation and ERG expression testing improves the currently used CN AML molecular risk classification.
  • METHODS: FLT3, NPM1, CEBPA and WT1 mutations and ERG and BAALC expression were tested at diagnosis in 143 CN AML adults enrolled on CALGB treatment protocols 9621 and 19808.
  • RESULTS: CALGB Group I (n=56) v Group II (n=87) had more complete remissions (CRs) (P=.005; 96% v 79%), and longer disease-free (DFS; P<.0001; 5 year (y) 69% v 21%) and overall (OS; P<.0001; 5 y 70% v 31%) survival [median follow-up for pts alive 6 y].
  • In contrast, for the same cohort of pts grouped by the FLT3-ITD/NPM1-only classification, CRs were 94% v 82% and 5 y DFS 59% v 32% and OS 67% v 36% in the Low- v High-risk groups.
  • CONCLUSIONS: Prognostic classification of younger de novo CN AML pts is improved by adding CEBPA and WT1 mutation and ERG expression testing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961374.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Naik SG, Negrin R, Laport G, Miklos D, Shizuru J, Arai S, Blume K, Wong R, Lowsky R, Johnston L: Long-term outcomes of high-dose therapy using busulfan, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for patients with high-risk or advanced stages of myeloid malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):7033

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of high-dose therapy using busulfan, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for patients with high-risk or advanced stages of myeloid malignancies.
  • : 7033 Patients (pts) with high risk (HR) or advanced myeloid malignancies have limited effective treatment options.
  • All pts were treated with a uniform preparatory regimen: busulfan 16.0 mg/kg (d-8 to-5), etoposide 60mg/kg (d-4), cyclophosphamide 60mg/kg (d-2), and graft-versus-host-disease (GVHD) prophylaxis of cyclosporine and prednisone.
  • Disease status at transplantation was induction failure (IF) acute myeloid leukemia (AML) (n = 10), HR AML in 1st complete remission (CR1) n = 11, in CR2 (n = 5), in CR3 (n = 2), relapsed refractory (RR) AML (n = 14), chronic myeloid leukemia (CML) in second chronic phase (n = 6), blast crisis (n = 2), myelofibrosis (n = 6), myeloproliferative disorders (n = 2), and MDS (n = 38).
  • Non-relapse mortality (NRM) was 29 % (95% CI 20%5-38%) at day 100 and 39% (95% CI 29%-49%) at one yr.
  • These results confirm that pts with high-risk or advanced myeloid malignancies can achieve long-term survival following myeloablative allogeneic HCT with aggressive conditioning.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961395.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Barret J, Dumontet C, Annereau J, Brel V, Breillout F, Guminski Y, Imbert T, Guilbaud N, Bailly C: A functional procedure using fresh samples to select patients with acute myeloid leukemia prior to treatment with the novel targeted cytotoxic agent F14512. J Clin Oncol; 2009 May 20;27(15_suppl):11087

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A functional procedure using fresh samples to select patients with acute myeloid leukemia prior to treatment with the novel targeted cytotoxic agent F14512.
  • This study was undertaken to investigate the potential of N-methyl-spermine-NBD, a proprietary fluorescent polyamine conjugate, designed to select patients with PTS-positive leukemic cells.
  • METHODS: The uptake of this probe was first measured by flow cytometry in a panel of human leukemia cell lines.
  • RESULTS: Data showed that high level of fluorescence was detected in F14512 -sensitive cancer cell lines whereas leukemia cells responding poorly to F14512 generally exhibited very low levels of PTS.
  • A panel of 50 fresh human acute myeloid leukemia samples showed a larger inter-individual variation and, interestingly, incorporation of the fluorescent probe was generally higher in leukemia blasts than in lymphocytes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963178.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Kim S, Lee J, Lee J, Kim D, Lim S, Lee Y, Kang Y, Seol M, Ryu S, Lee K: Pretransplant comorbidity as an outcome predictor in adult patients younger than 60 years of age receiving standard induction chemotherapy for de novo acute myeloid leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):7055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretransplant comorbidity as an outcome predictor in adult patients younger than 60 years of age receiving standard induction chemotherapy for de novo acute myeloid leukemia.
  • : 7055 Background: Comorbidity has been evaluated as an outcome predictor in elderly patients receiving induction chemotherapy for acute myeloid leukemia (AML) as well as in patients undergoing allogeneic hematopoietic cell transplantation (HCT) for various hematologic disorders.
  • METHODS: A total of 276 patients, aged 14 to 59 years, who received standard induction chemotherapy consisting of cytarabine plus daunorubicin or idarubicin for de novo AML excluding M3 subtype between 2000 and 2007 were included.
  • Pre-treatment comorbidity score, assessed by the HCT specific comorbidity index (HCT-CI), was calculated using clinico- pathologic data, which were retrieved from Asan Medical Center Leukemia Registry Database.
  • CONCLUSIONS: Pre-treatment comorbidity may provide additional prognostic information over established prognostic factors in patients younger than 60 years of age receiving standard induction chemotherapy for de novo AML.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961421.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Villano JL, Letarte N, Yu JM, Shakir AR, Bressler L: Hematologic adverse events associated with temozolomide (TMZ). J Clin Oncol; 2009 May 20;27(15_suppl):2053

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2053 Background: Secondary acute myeloid leukemia (AML) is reported to occur in 3%-10% of patients treated with alkylating agents for Hodgkin's lymphoma, non-Hodgkin's lymphoma, ovarian cancer, breast cancer, and multiple myeloma.
  • Among these patients, we identified 140 cases that we labeled as major hematologic adverse events: agranulocytosis (8 cases), aplasia (42), aplastic anemia (52), leukemia (26), MDS (6), and lymphoma (6).
  • Risk of leukemia/MDS from our review may also be significant, but length of follow-up is insufficient and the real risk is likely still unknown.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964671.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Robertson KA, Colvin ES, Kelley MR, Fishel ML: APX3330 inhibition of the redox function of ape-1/ref-1 (Ref-1) in promyelocytic leukemia cells enhances retinoic acid (ATRA) induced myeloid differentiation and limits cell proliferation as an approach to the prevention of the retinoic acid syndrome (RAS). J Clin Oncol; 2009 May 20;27(15_suppl):e14613

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] APX3330 inhibition of the redox function of ape-1/ref-1 (Ref-1) in promyelocytic leukemia cells enhances retinoic acid (ATRA) induced myeloid differentiation and limits cell proliferation as an approach to the prevention of the retinoic acid syndrome (RAS).
  • : e14613 Background: ATRA + chemotherapy has improved the treatment of promyelocytic leukemia(APL).
  • One approach to prevent RAS is to limit blast proliferation and enhance myeloid differentiation.
  • HL60 myeloid leukemia cells are promyeloblasts that respond to ATRA with granulocytic differentiation/growth arrest.
  • Differentiation was evaluated by morphology and expression of CD11b by flow cytometry.
  • CONCLUSIONS: APX3330 + ATRA limits HL60 growth and dramatically enhances terminal granulocytic differentiation.
  • These finding may provide a therapeutic approach for prevention of the RAS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964118.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Hoffman KR: Understanding among medical oncologists of the true monetary cost of therapy. J Clin Oncol; 2009 May 20;27(15_suppl):6629

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 50 medical oncologists agreed to take a survey judging their knowledge of the financial cost of the treatments used in patients with the five most common tumors treated in the office: breast cancer, non-small cell lung cancer, colorectal cancer, non-Hodgkin's lymphoma, and three other commonly treated cancers: chronic myelogenous leukemia, multiple myeloma and ovarian cancer.
  • More education is needed in the economics, including monetary cost-benefit analysis, of oncology practice so that we can better serve our patients and society.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961808.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Bello CM, Yu D, Zhu W, Wetzstein GA, Lancet JE: Outcomes following induction chemotherapy in patients with AML arising from MDS: Analysis of prognostic factors. J Clin Oncol; 2009 May 20;27(15_suppl):7088

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7088 Background: Secondary acute myeloid leukemia (sAML) arising from myelodysplasia (MDS) or a myeloproliferative neoplasm (MPN) has a poor prognosis.
  • RESULTS: Sixty-one patients with sAML who received induction therapy were evaluated: median age (range) = 66 (36-82) years; M = 67%, ECOG PS 0 or 1 = 86%; poor-risk (PR) cytogenetics = 33%; IPSS > 1 = 43%; prior therapy for MDS with decitabine or azacitidine (DM) or lenalidomide (L) = 41% (25 pts).
  • Multivariable analysis indicated that the same three factors were significantly negatively associated with CR/CRp as well as OS: PR cytogenetics, prior treatment with DM/L, and long transformation to AML on log scale.
  • Only 32% of the group that received prior treatment with a DM/L achieved CR/CRp compared to 78% in non DM/L-treated patients (OR = 0.13, 95% CI: 0.04-0.42).
  • The CR/CRp rate for those with intermediate risk (IR) cytogenetics was 70% compared to only 35% for those with PR cytogenetics (OR = 4.33, 95% CI: 1.38-13.6).
  • Those with PR cytogenetics had a median OS of 2.8 mo compared to 7.5 mo for IR (p = 0.01).
  • The median OS for those treated with a DM/L was 3.7 mo compared to 10.5 mo for non DM/L-treated patients (p < 0.0001).
  • CONCLUSIONS: Prior MDS treatment with a DM/L, PR cytogenetics and long transformation to AML are independent negative prognostic factors for response and OS in patients with sAML following induction therapy, suggesting that such patients may be better served by novel approaches, and that stratification for these risk factors should be considered in future clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961482.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Sampat KR, Garcia-Gutierrez V, Rossi A, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G: Prevalence and therapeutic relationships of pericardial effusions in patients with leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):7067

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and therapeutic relationships of pericardial effusions in patients with leukemia.
  • : 7067 Background: Little is known regarding the prevalence and natural history of pericardial disease in patients with leukemia.
  • To study this issue, we retrospectively analyzed a large cohort of patients with leukemia, who were evaluated at MD Anderson Cancer Center (MDACC), to determine the prevalence, timing, and characteristics of PEf in leukemia.
  • METHODS: We reviewed 3,327 patients with acute myeloid leukemia (AML, N = 1,809, 54%), acute lymphocytic leukemia (ALL, N = 494, 15%), or myelodysplastic syndrome (MDS, N =1,024, 31%), who were seen at MDACC from August 2003 to July 2008.
  • Data regarding diagnosis, timing, effusion size, and prior therapy was collected in the 401 patients (20.2%) that had echocardiographic evidence of PEf.
  • In the 401 total patients with PEf, 22.8%, 25.0%, and 18.4% (p = 0.33) of these effusions were found before treatment in the three disease categories, respectively.
  • The rest occurred after some form of chemotherapy, accounting for 77.2%, 75.0%, and 81.6% (p = 0.73) of the total PEf by disease, respectively.
  • CONCLUSIONS: PEf are relatively common in patients with leukemia at initial presentation and are usually asymptomatic.
  • Their incidence increases with therapy administration although it appears that this is not a process related to specific classes of treatment or type of leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961462.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Giles FJ, O'Brien S, Rizzieri DA, Vey N, Krug U, Sekeres M, Jacobsen TF, Nilsson BI, Staudacher K: A phase II study with CP-4055 in patients with second salvage AML. J Clin Oncol; 2009 May 20;27(15_suppl):7047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to assess efficacy and safety of CP-4055 when given as second salvage therapy to patients (pts) with acute myeloid leukemia (AML).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961426.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Bruey J, Kantarjian H, Ma W, Yeh C, Peralta R, Lee T, O'Brien S, Estrov Z, Cortes J, Albitar M: Alternatively spliced truncated BCR-ABL1 protein in CML patients with resistance to kinase inhibitors. J Clin Oncol; 2009 May 20;27(15_suppl):7026

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7026 Background: We have reported that some patients with imatinib-resistant chronic myeloid leukemia (CML) express an alternatively spliced BCR-ABL mRNA with a 35-bp insertion (BCR-ABL1<sup>35INS</sup>), resulting in the addition of 10 residues and truncation of 653 residues.
  • Here we evaluate the prevalence of BCR-ABL1<sup>35INS</sup> in imatinib-resistant CML, examine the effect of this mutation on resistance to compared the efficiency of various kinase inhibitors in vitro, and suggest a model for persistent CML and a possible strategy to eradicate residual disease.
  • CONCLUSIONS: These findings emphasize the importance of the overlooked alternatively spliced BCR-ABL1<sup>35INS</sup> protein and may provide a strategy to treat resistant disease and eradicate residual CML.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961399.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Batty G, Kantarjian H, Issa JJ, Garcia-Manero G, Pierce S, O'Brien S, Jabbour E, Cortes J, Ravandi F: Feasibility of hypomethylating therapy in patients with renal insufficiency. J Clin Oncol; 2009 May 20;27(15_suppl):7089

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We investigated the outcomes of pts with RI and MDS, chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML) receiving therapy with HA.
  • We used the International Working Group criteria to evaluate the response rates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961273.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Biswajit D, Rejiv R, Manjunath N, Prasad G, Lakshmi S, Devika P, Geetha K, Sagar TG: Imatinib mesylate experience of young patients with chronic myeloid leukemia in chronic phase-Care to cure. J Clin Oncol; 2009 May 20;27(15_suppl):7072

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate experience of young patients with chronic myeloid leukemia in chronic phase-Care to cure.
  • : 7072 Background: Chronic myeloid leukemia (CML) with introduction of imatinib has been transformed into a chronic illness.
  • The other common non hematological toxicities included pedal edema (13.7%), hypo or hyper pigmentation (60.0%), hyalgia (14.5%), diarrhea (1.6%), and liver dysfunction (1.6%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961455.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Stone RM, Kim DW, Kantarjian HM, Rousselot P, Hochhaus A, Dorlhiac-Llacer PE, Milone J, Matloub Y, Lambert A, Shah NP: Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): Three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression-free survival (PFS). J Clin Oncol; 2009 May 20;27(15_suppl):7007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): Three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression-free survival (PFS).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961379.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Iacobucci I, Storlazzi C, Lonetti A, Ferrari A, Messina M, Cilloni D, Papayannidis C, Baccarani M, Foà R, Martinelli G: IKZF1 (IKAROS) deletions as a prognostic marker in BCR-ABL1 positive acute lymphoblastic leukemia patients: A GIMEMA ALL WP Report. J Clin Oncol; 2009 May 20;27(15_suppl):11005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IKZF1 (IKAROS) deletions as a prognostic marker in BCR-ABL1 positive acute lymphoblastic leukemia patients: A GIMEMA ALL WP Report.
  • : 11005 Expression of BCR-ABL1 in hematopoietic stem cells can alone induce a chronic myeloid leukemia (CML) but cooperating oncogenic lesions are required for the generation of a blastic leukemia.
  • To identify oncogenic sub-microscopic lesions that cooperate with BCR-ABL1 to induce ALL, by high resolution single nucleotide polymorphism (SNP) arrays (250K NspI and SNP 6.0, Affymetrix) we studied 106 patients (pts) with de novo adult BCR-ABL1-positive ALL.
  • Univariate analysis showed that the IKZF1 deletion is a negative prognostic marker influencing the cumulative incidence of relapse (10.1 months for pts with deletion vs 56.1 months for wild-type pts, p=0.0103) and disease-free survival (DFS) (10.1 months vs 32.1 months, respectively, p=0.0229).
  • Supported by European LeukemiaNet, AIL, AIRC, FIRB 2006, Strategico di Ateneo, GIMEMA Onlus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964054.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Duhoux F, Libouton J, Bahloula K, Ameye G, Poirel HA: Identification by FISH of 4 novel partner loci of PRDM16 in myeloid malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):11037

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification by FISH of 4 novel partner loci of PRDM16 in myeloid malignancies.
  • : 11037 Background: PRDM16 is a gene located on 1p36.32 that encodes for a zinc finger transcription factor and contains an N-terminal PR domain.
  • It has been shown to be involved in the reciprocal translocation t(1;3)(p36;q21) and more rarely the t(1;21)(p36;q22) which both occur in myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML).
  • These translocations result in the overexpression of a truncated version of the PRDM16 protein that lacks the PR domain.
  • This overexpression might play an important role in the pathogenesis of MDS and AML in blocking myeloid differentiation.
  • METHODS: We studied 35 myeloid malignancies, 12 lymphoid malignancies and 3 undifferentiated acute leukemias with 1p36 abnormalities by fluorescent in situ hybridization (FISH) with a bacterial artificial chromosomes (BAC) contig containing 50 BAC probes on 1p36.
  • RESULTS: In addition to the known t(1;3)(p36;q21) (11 cases) and t(1;21)(p36;q22) (1 case) involving RPN1 andAML1/RUNX1 respectively in myeloid malignancies, we specifically found PRDM16 to be rearranged in 4 additional translocations : a t(1;12)(p36;p13) in an AML-M4, a t(1;7)(p36;p12) in a MDS, an add(1)(p36) in an AML-M2 and a t(1;2)(p36;p12) in a relapsed AML-M4.
  • We identified the respective candidate partner loci : TEL/ETV6, IKZF1, CDH4 and a non-coding unknown sequence.
  • CONCLUSIONS: In our series of 50 cases of hematological malignancies with 1p36 abnormalities, PRDM16 was involved in about 45% of myeloid malignancies, and was never involved in lymphoid malignancies.
  • PRDM16 is supposed to have similar oncogenic properties as MDS1/EVI-1(3q26), another gene encoding for a zinc finger protein and acting as a transcriptional regulatory factor with 2 isoforms.
  • Interestingly, the shortest isoform of MDS/EVI-1, lacking the PR domain, is supposed to have an oncogenic effect due to its translocation-induced upregulation in AML.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964015.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Cheng PC, Crane J, Hunter T: Combination of bortezomib with a FLT3 inhibitor potentiates inhibition of proliferation and apoptosis of AML in vitro. J Clin Oncol; 2009 May 20;27(15_suppl):e14551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14551 Background: FLT3 receptor tyrosine kinase activating mutations contribute to leukemogenesis and poor prognosis in approximately 30% of acute myeloid leukemia (AML).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963616.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Ayan I, Kebudi R, Ozger H, Yaman Agaoglu F, Gorgun O, Bilgic B, Eralp L, Dizdar Y, Darendeliler E: Childhood osteosarcoma: Evaluation of 94 cases. A single institution study. J Clin Oncol; 2009 May 20;27(15_suppl):10040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between January 1990 and December 2006, 94 children (53 male, 41 female) with a median age of 13 (5-16) years and a histopathologic diagnosis of osteosarcoma were treated with an institutional chemotherapy regimen comprising of 6 courses (3 pre-, 3 postoperatively) of epirubicin (90 mg/m2), cisplatin(100 mg/m2), and ifosfamide(2 g/m2 × 3 days) every 3 weeks.
  • 26 patients died; 20 of disease, 5 of toxicity, and 1 of second malignancy (acute myeloid leukemia).
  • 5 and 10 year EFS for nonmetastatic patients was superior to those with metastatic disease [62.4 % (95% CI 49.9-79.9 %) vs. 6.9 % (95% CI 0-19.9 %)) (p<0.001).
  • 10 year OS for 18 patients (11 metastatic at diagnosis) who progressed during preoperative chemotherapy was 13 % vs. 75 % for those who didnot have progressive disease (p< 0.001).
  • CONCLUSIONS: The presence of metastases at diagnosis was the most significant characteristic influencing outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962466.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Veuillen C, Gravis G, Marcy M, Walz J, Bladou F, Salem N, Brunelle S, Olive D: Alterations of natural killer cells in metastatic prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, our group have reported that patients with acute myeloid leukaemia have defective interactions receptor -ligand in NK cells due to a decreasing expression of Natural Cytotoxicity Receptors and it could be used as a evasion mechanism by leukaemia cells.
  • Is it hormonal therapy or extension of the disease that is responsible of NK cells alterations?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963371.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Khoury HJ, Lima L, Saxe D, Mann KP, Arellano M, Heffner L, Bernal-Mizrachi L, McLemore M, Langston A, Winton E: Monitoring chronic myeloid leukemia (CML) response to tyrosine kinase inhibitors (TKI) and homoharringtonine (HHT) using peripheral blood (PB) fluorescence in situ hybridization (FISH) and quantitative RT-PCR (Q-PCR): Are bone marrow biopsies still needed? J Clin Oncol; 2009 May 20;27(15_suppl):7064

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring chronic myeloid leukemia (CML) response to tyrosine kinase inhibitors (TKI) and homoharringtonine (HHT) using peripheral blood (PB) fluorescence in situ hybridization (FISH) and quantitative RT-PCR (Q-PCR): Are bone marrow biopsies still needed?
  • Correlation was not affected by the presence of additional chromosomal abnormalities, phase of the disease, treatment (TKI or HHT), or the number of prior therapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961440.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Jabbour E, Faderl S, Ravandi F, Konopleva M, Verstovsek S, Cortes J, Wierda W, Newsome WM, Yang H, Kantarjian H, Garcia-Manero G: Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodyplsatic syndrome (MDS) or acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodyplsatic syndrome (MDS) or acute myeloid leukemia (AML).
  • 8 (47%) had secondary disease.
  • Results will be compared with those of a parallel IA study at MDACC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961376.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Lima L, Assouline SE, Saxe D, Mann K, McLemore M, Souza L, Arellano M, Winton EF, Bernal-Mizrachi L, Khoury HJ: Does pre-imatinib (IM) fluorescence in situ hybridization (FISH) predict myelosuppression and outcomes in chronic myeloid leukemia (CML)? J Clin Oncol; 2009 May 20;27(15_suppl):7071

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does pre-imatinib (IM) fluorescence in situ hybridization (FISH) predict myelosuppression and outcomes in chronic myeloid leukemia (CML)?
  • Myelosuppression AP pts expired (CML=2, GVHD=1); 1 after complete hematologic (CHR) and minor cytogenetic response (CTGR), 1 after partial HR, and 1 resistant disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961454.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Ghadyalpatil N, Banawali S, Kurkure P, Arora B, Bansal S, Amare P, Choughule A, Soy L, Singh R: Efficacy and tolerability of imatinib mesylate in pediatric chronic myeloid leukemia in a large cohort: Results from a tertiary care referral center in India. J Clin Oncol; 2009 May 20;27(15_suppl):10047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and tolerability of imatinib mesylate in pediatric chronic myeloid leukemia in a large cohort: Results from a tertiary care referral center in India.
  • : 10047 Background: Chronic myeloid leukemia (CML) is a rare disease in children and there is limited data of safety and efficacy of imatinib mesylate (IM) in this age group.
  • METHODS: We analyzed the outcomes of 48 consecutive children (September 1998 to December 2008) in chronic phase (CP) or accelerated phase (AP) CML not eligible for Allo-SCT and were treated with IM [Glivec (Novartis), through patient assistance programme GIPAP or Veenat (NATCO), generic brand for GIPAP ineligible patients] within 12 months of diagnosis.
  • RESULTS: The median age at the time of diagnosis was 12 years (range 3-18 years).
  • One patient had secondary IM resistance and had progressive disease even on dose escalation.
  • Two patients in AP at diagnosis achieved CCR at 5 and 7 months and continue to be in CCR.
  • Significant non hematological toxicities were uncommon except for hypopigmentation which was seen in more than half the cohort.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962473.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Pardee TS, Zuber J, Lowe SW: Effects of the Flt3 ITD on response to chemotherapy in a murine model of acute myeloid leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):7060

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of the Flt3 ITD on response to chemotherapy in a murine model of acute myeloid leukemia.
  • : 7060 Background: Acute myeloid leukemia (AML) is an aggressive, genetically heterogeneous malignancy.
  • Blasts were harvested from moribund animals and myeloid lineage confirmed by immunophenotyping.
  • For in vivo competition assays animals were injected with mixtures of blasts, treated with chemotherapy and percentages of Flt3 ITD positive blasts as well as total leukemic burden in femoral bone marrow was assessed.
  • Ara-C treated animals had fewer Flt3 ITD blasts than controls (p = 0.0030) or dox treated animals (p < 0.0001) and lower leukemic burden (p < 0.0001).
  • In contrast there was no difference in leukemic burden between Ara-C treated, dox treated or control animals in AML without Flt3 ITD (p = 0.2833).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961434.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Tsujimura H, Mimura N, Ise M, Sakai C, Shimada H, Nagata M, Kumagai K: Incidence of therapy-related leukemia following chemoradiotherapy for esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15663

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of therapy-related leukemia following chemoradiotherapy for esophageal cancer.
  • RESULTS: Four patients, who achieved CR after CRT, developed leukemia.
  • Case1, 60-yo-male, developed overt acute myeloid leukemia (AML) from myelodysplastic syndrome 48 months after CRT.
  • Case3, 72-yo-male, developed Burkitt leukemia with t(8;14)(q24;q32) 19 months after CRT.
  • Case4, 65-yo-male, developed myeloid crisis of chronic myelogenous leukemia with complicated abnormalities including t(9;22)(q34;q11) 48 months after CRT.
  • Case 1 and 3 had localized disease and received single course of neoadjuvant CRT.
  • Case 2 and 4 had advance disease and received 2 courses of CRT.
  • All patients eventually died of leukemia.
  • To this end, atypical cytogenetic abnormalities seen in the present cases give a new insight into the biology of therapy-related leukemia.
  • Notably, this is the first report presenting the incidence of secondary leukemia by nedaplatin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962759.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Nicolini FE, Mahon FX, Guilhot J, Buzyn A, Tulliez M, Berthou C, Christian B, Guyotat D, Preudhomme C, Guilhot F: A phase III study exploring various doses of imatinib (IM) or IM in combination for newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) patients (pts): Results of an interim analysis of the SPIRIT trial of French CML group. J Clin Oncol; 2009 May 20;27(15_suppl):7058

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III study exploring various doses of imatinib (IM) or IM in combination for newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) patients (pts): Results of an interim analysis of the SPIRIT trial of French CML group.
  • Grade 3/4 non-hematological toxicities occurred in 19% IM-400 (edemas, muscle cramps), 30% IM-600, 27% IM-Ara-C (diarrhea) and 31% IM-PegIFN pts (skin rashes, asthenia).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961449.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Erba HP, Kantarjian HM, Claxton DF, Arellano M, Lyons RM, Kovacsovics TJ, Gabrilove J, Eckert S, Faderl S: Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor(s). J Clin Oncol; 2009 May 20;27(15_suppl):7062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor(s).
  • We now report updated duration of remission (DOR), disease-free survival (DFS), and overall survival (OS).
  • METHODS: Single arm, multi-center, phase II, open-label, 2-stage study of patients with untreated AML, ≥60 years old, and at least one adverse prognostic factor: age ≥70 years, antecedent hematologic disorder (AHD), PS = 2, and/or intermediate/unfavorable risk karyotype.
  • Clofarabine (CLO) administered days 1-5 at 30 mg/m<sup>2</sup> during induction and 20 mg/m<sup>2</sup> during re-induction/consolidation for maximum 6 cycles.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961436.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Kunivayalil S, Jain A, Satheesh C, Tejinder S, Lakshmaiah K, Suresh TM, Lokanatha D, Babu G: A comparative study of single-dose pegfilgrastim versus daily filgrastim in patients with acute myeloid leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):e18005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparative study of single-dose pegfilgrastim versus daily filgrastim in patients with acute myeloid leukemia.
  • It can be used during induction and consolidation chemotherapy in acute myeloid leukemia (AML).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964003.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Stanek E, Aubert RE, Sanders C, Frueh FW, Yao J, Epstein RS: Inadequate BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):7077

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inadequate BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia.
  • : 7077 Background: Recommendations for baseline and quarterly measurement of the BCR-ABL fusion transcript to monitor imatinib response in patients with chronic myelogenous leukemia (CML) were formally introduced in October 2006, and have been incorporated into nationally recognized treatment guidelines.
  • The study cohort was defined as patients with an index imatinib pharmacy claim from July 1, 2006, to December 31, 2006, who had a CML diagnosis (ICD-9 205.1X; N = 504), and a minimum of 3 months continuous follow-up by claims history (N = 465).
  • Over a period of up to four quarters from the index imatinib prescription date, BCR-ABL testing in each quarter was assessed by the presence of any of a set of 19 CPT-4 codes.
  • CONCLUSIONS: In this retrospective claims database analysis, only 14% of a large cohort of CML patients treated with imatinib had BCR-ABL testing recorded in each of 4 consecutive quarters.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961460.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Ding W, Knox TR, Smoley SA, Van Dyke DL, Kay NE: Cytogenetic abnormalities in mesenchymal stem cells in chronic lymphocytic leukemia (CLL) patients and normal subjects. J Clin Oncol; 2009 May 20;27(15_suppl):e22002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic abnormalities in mesenchymal stem cells in chronic lymphocytic leukemia (CLL) patients and normal subjects.
  • Recent reports have described clonal cytogenetic abnormalities in the MSC of acute myeloid leukemia and myelodysplastic syndrome patients.
  • After 3-4 non-stimulated cell culture passages, the karyotype was analyzed in 5-40 metaphase cells from each subject Abnormalities were considered clonal using the accepted convention of the same chromosomal gain or rearrangement in 2 or more cells or loss in at least 3 cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963169.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Chamberlain MC, Raizer J: Extended exposure to alkylator chemotherapy: Delayed appearance of myelodysplasia. J Clin Oncol; 2009 May 20;27(15_suppl):e13030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: A case series of gliomas treated with alkylator-based chemotherapy who subsequently developed myelodysplastic syndrome (tMDS) or acute myelocytic leukemia (AML).
  • The diagnosis of tMDS was determined by bone marrow biopsy in seven patients.
  • Interval from last chemotherapy exposure to diagnosis of tMDS/AML ranged from 3 months to 31 months (median 24 months).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962878.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff D, Kuderer NM, Lambert K, Crawford J: Acute myeloid leukemia or myelodysplastic syndrome (AML/MDS) and overall mortality with chemotherapy (CT) and granulocyte colony-stimulating factor (G-CSF): A meta-analysis of randomized controlled trials (RCTs). J Clin Oncol; 2009 May 20;27(15_suppl):9524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia or myelodysplastic syndrome (AML/MDS) and overall mortality with chemotherapy (CT) and granulocyte colony-stimulating factor (G-CSF): A meta-analysis of randomized controlled trials (RCTs).
  • No differences in estimates of AML/MDS or mortality were observed between industry and non-industry-funded studies.
  • Further research is needed to differentiate any impact of G-CSF on the risk of AML/MDS from that due to increased CT intensity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964513.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Mahon Fx F, Rea D, Guilhot F, Legros L, Guilhot J, Aton E, Dulucq S, Reiffers J, Rousselot P: Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation: Interim analysis of the STIM trial. J Clin Oncol; 2009 May 20;27(15_suppl):7084

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation: Interim analysis of the STIM trial.
  • : 7084 Background: Imatinib (IM) has greatly improved survival in chronic myeloid leukemia (CML).
  • METHODS: Inclusion criteria were IM treatment duration ≥3 years and sustained CMR, defined as BCR-ABL transcripts below a detection threshold of a 5-log reduction (undetectable by RQ-PCR) for ≥2 years.
  • Molecular monitoring was performed according to international recommendations.
  • Median age was 62 (29-80), 31 pts had been treated with IFN prior to IM and 29 with IM frontline (de novo).
  • At M9, the probability of persistent CMR was 46% (95% CI: 32-59%), 53% (95% CI: 33-69%) for previously IFN-treated pts and 39% (95% CI: 20-58%) for de novo pts (p = 0.54).
  • A trend for a lower probability of relapse in low Sokal score pts was observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961477.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Vey N, Bourhis J, Dombret H, Bordessoule D, Prebet T, Charbonnier A, Squiban P, Damholt B, Blaise D, Olive D: A phase I study of the anti-natural killer inhibitory receptor (KIR) monoclonal antibody (1-7F9, IPH2101) in elderly patients with acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):3015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of the anti-natural killer inhibitory receptor (KIR) monoclonal antibody (1-7F9, IPH2101) in elderly patients with acute myeloid leukemia (AML).
  • In some models, it has been shown that KIR mismatch is important for the anti-leukemic effect of the graft, most probably through unleashed NK cells towards AML blasts, as suggested by enhanced in vitro NK lytic activity of KIR-HLA mismatched donor NK against recipient blasts.
  • METHODS: Patients aged 60-80 years with non promyelocytic AML in first CR following induction and 1-6 cycles of consolidation chemotherapy, normal renal, and hepatic functions, KIR-expression on patient NK-cells and who signed informed consent were eligible.Dose escalation (0.0003, 0.003, 0.015, 0.075, 0.3, 1, 3 mg/kg) was studied using a 3+3 scheme.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962059.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Maris MB, Ravandi F, Stuart R, Stone R, Cripe L, Cooper M, Strickland S, Turturro F, Stock W, Berman C: A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7048

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML).
  • Eligibility: newly diagnosed AML (de novo or secondary AML), pts age ≥ 60 and ≥ 1 additional adverse risk factor (age ≥ 70, secondary AML, intermediate or unfavorable cytogenetics, or PS 2).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961427.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Kantarjian H, Giles F, Bhalla K, Pinilla J, Larson RA, Gattermann N, Ottmann OG, Gallagher NJ, Baccarani M, leCoutre P: Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):7029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study.
  • Gr 3/4 non-hematologic AEs were infrequent: rash, headache, and diarrhea occurred in 2% of pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961402.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Stuart RK, Stockerl-Goldstein K, Cooper M, Devetten M, Herzig R, Medeiros B, Schiller G, Wei A, Acton G, Rizzieri D: Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML).
  • CONCLUSIONS: Data from this first phase II trial of an aptamer in oncology are encouraging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961391.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Ravandi Kashani F, Cortes J, Faderl S, Jones D, Byrd A, Brandt M, Garcia-Manero G, Levis M, Andreeff M, Kantarjian H: Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML).
  • METHODS: Objectives of this study are to determine the tolerability and efficacy of combination of S with chemotherapy.
  • In the phase I part, pts with relapsed AML were treated with escalating doses of S (400 mg qod, 400 mg daily, 400 mg bid) for 7 days during induction, and 400 mg bid was established as safe.
  • Correlative studies confirm potent activity of S against FLT3 signaling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961390.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Cortes JE, Khoury HJ, Corm S, Nicolini F, Schenk T, Jones D, Hochhaus A, Craig AR, Humphriss E, Kantarjian H, Omacetaxine 202 Study Group: Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: Data from an ongoing phase II/III trial. J Clin Oncol; 2009 May 20;27(15_suppl):7008

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: Data from an ongoing phase II/III trial.
  • Median disease duration is 58 mos.
  • Grade 3/4 non-hematologic events are diarrhea (2%) and fatigue (4%).
  • CONCLUSIONS: Omacetaxine in T315I+ CML Pts results in de-selection of the T315I clone and induces hematologic and cytogenetic responses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961380.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Lorico A, Anzanello F, Rappa G: Imatinib-induced changes in gene expression and the metastatic potential of human breast carcinoma cells. J Clin Oncol; 2009 May 20;27(15_suppl):1074

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since its advent for the successful treatment of chronic myelogenous leukemia in 2001, the clinical efficacy of imatinib has been investigated in many other human malignancies, including breast cancer.
  • Based on recent reports that chemotherapy selects more invasive and metastasizing cells, we have hypothesized that exposure of breast cancer cells to imatinib could enhance their malignant behavior.
  • RESULTS: In vitro, imatinib treatment increased the motility and invasiveness of the breast cancer cells, and induced over-expression of drug transporters and of a set of genes associated with aggressive and metastatic behavior (Table).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961213.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Martinelli G, Castagnetti F, Poerio A, Breccia M, Palandri F, Alimena G, Pane F, Saglio G, Baccarani M, Rosti G: Molecular responses with nilotinib 800 mg daily as first-line treatment of chronic myeloid leukemia in chronic phase: Results of a phase II trial of the GIMEMA CML WP. J Clin Oncol; 2009 May 20;27(15_suppl):7074

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular responses with nilotinib 800 mg daily as first-line treatment of chronic myeloid leukemia in chronic phase: Results of a phase II trial of the GIMEMA CML WP.
  • It is noteworthy, considering the 48 cases with at least 6 months of follow-up, that the incidence of any grade 2 and 3 non-hematologic adverse event, decreased from 50% and 8% (first 3 months) to 23% and 6% (second trimester), respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961457.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Borthakur G, Faderl S, Ravandi F, Padmanabhan S, Stock W, Wu K, Li J, Curt G, Tallman M, Minden M: Clinical, pharmacokinetic (PK), and pharmacodynamic findings from a phase I trial of an Eg5 inhibitor (AZD4877) in patients with refractory acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):3580

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, pharmacokinetic (PK), and pharmacodynamic findings from a phase I trial of an Eg5 inhibitor (AZD4877) in patients with refractory acute myeloid leukemia (AML).
  • The T<sub>1/2</sub> of AZD4877 ranged from 26 to 42 hr; PK were linear and drug levels non-cumulative.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961757.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Raza A, Galili N, Borthakur G, Carter TH, Claxton DF, Erba HP, DeAngelo DJ, Berger MS, Schimmer A: A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):3579

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961704.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Mir AR Jr, Sazawal Sazawal S, Saxena A, Saxena R: High-sensitivity detection of M351T, F317L, and F311C BCR-ABL kinase domain mutation in chronic myeloid leukemia patients treated with novel tyrosine kinase inhibitors (TKIs) imatinib and dasatinib. J Clin Oncol; 2009 May 20;27(15_suppl):7061

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-sensitivity detection of M351T, F317L, and F311C BCR-ABL kinase domain mutation in chronic myeloid leukemia patients treated with novel tyrosine kinase inhibitors (TKIs) imatinib and dasatinib.
  • 2/5 died, three progressed to advanced disease.
  • After 10 months, 4/10 developed a more fatal mutation in 315 and consequently 2/4 died and one progressed to advanced disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961435.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Wetzler M, Hellmann A, Lipton J, Roy L, Jones D, Schenk T, Hochhaus A, Benichou A, Kantarjian H, Cortes J, Omacetaxine 203 Study Group: Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): Data from an ongoing phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):7027

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): Data from an ongoing phase II trial.
  • Median disease duration: 74 months.
  • Grade 3/4 non-hematologic events are rare with pyrexia occurring in 4.3% of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961400.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Lonetti A, Iacobucci I, Ferrari A, Messina M, Cilloni D, Soverini S, Papayannidis C, Baccarani M, Foà R, Martinelli G: Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients. J Clin Oncol; 2009 May 20;27(15_suppl):7049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients.
  • : 7049 Since the activation-induced cytidine deaminase (AID) enzyme can target non-immunoglobulin (Ig) genes and may even act as a genome-wide mutator, we investigated AID expression in BCR-ABL1-positive ALL and in chronic myeloid leukemia (CML) at the time of progression to blast crisis.
  • On the 61 de novo adult BCR-ABL1-positive ALL patients (pts), AID mRNA and protein were detected in 36 (59%); their expression correlated with BCR-ABL1 transcript levels and disappeared after treatment with tyrosine kinase inhibitors at the time of remission.
  • AID expression was also found in lymphoid blast crisis CML (50%), but not in myeloid lineage or in chronic phase CML.
  • Our findings show that BCR-ABL1-positive ALL cells aberrantly express different isoforms of AID that can act as mutator outside the Ig gene loci in promoting genetic instability in leukemia cells.
  • Supported by: European LeukemiaNet, AIL, AIRC, FIRB 2006, Fondazione del Monte di Bologna e Ravenna, Strategico di Ateneo, GIMEMA Onlus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961429.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Gupta A, Singh M, Singh H, Kumar L, Sharma A, Bakhshi S, Raina V, Thulkar S: Febrile neutropenia during acute myeloid leukemia therapy: Single institution experience from a developing country. J Clin Oncol; 2009 May 20;27(15_suppl):e18000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Febrile neutropenia during acute myeloid leukemia therapy: Single institution experience from a developing country.
  • : e18000 Background: Febrile neutropenia poses a major challenge during treatment of acute myeloid leukaemia (AML).
  • METHODS: Episodes of febrile neutropenia in 104 consecutive patients of AML admitted to the medical oncology ward between May 2001 and December 2006 were studied.
  • RESULTS: 402 febrile episodes including 363 episodes of febrile neutropenia (180 in induction, 183 in consolidation) and 39 non-neutropenic episodes (18 in induction, 21 in consolidation) occurred.
  • Prompt and proper institution of antibiotics and antifungals besides considering alternative diagnosis peculiar to the region (e.g. tuberculosis, malaria) may aid in better management.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964014.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Sokolova MA, Khoroshko ND, Tsvetaeva NV, Semenova EA, Kaplanskaia IB, Frank GA, Misiurin AV: [Study of bone marrow microvessel density is one of the diagnostic approaches in patients with Ph-negative chronic myeloproliferative diseases]. Ter Arkh; 2010;82(12):47-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of bone marrow microvessel density is one of the diagnostic approaches in patients with Ph-negative chronic myeloproliferative diseases].
  • AIM: To define an association of bone marrow microvessel density (MVD) with histological properties (the magnitude of fibrosis and quantification of megakaryocytes (MGKC)) in patients with Ph-negative chronic myeloproliferative diseases (CMPD).
  • True polycythemia (TP) was present in 28 patients; 20 patients had essential thrombocythemia (ET), 36 had subleukemic myelosis, out them 6 were in a prefibrotic stage, and 9 with diagnosed post-TP (ET) myelofibrosis.
  • The patients with PMF had high MVD values [6.5 (range 2.8-22)] than those with TP [4.0 (range 1.76-10.2)] or ET [3.7 (range 2-8.5)] and the controls [3.2 (range 2-4.1)] (p < 0.001) confirming that angiogenesis is uninvolved at the onset of disease in patients with ET and those with TP.
  • CONCLUSION: Bone marrow angiogenesis assessment (from MVD measurements) may be an additional criterion for the diagnosis of disease evolution and an additional criterion between ET and PMF in a prefibrotic stage.
  • [MeSH-major] Bone Marrow / blood supply. Microvessels / pathology. Myeloproliferative Disorders / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Chronic Disease. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neovascularization, Pathologic / pathology. Reproducibility of Results. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21516739.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


89. Kuriyama K: [Classification of myeloid leukemias]. Nihon Rinsho; 2009 Oct;67(10):1853-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Classification of myeloid leukemias].
  • Myeloid leukemia in this series corresponds to the myeloid neoplasms of the 4th WHO classification of pathology and genetics of tumor of haematopoietic and lymphoid tissue.
  • The myeloid neoplasms are composed of six categories, which are 1) myeloproliferative neoplasms (MPN), a new category of 2) myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1, 3) myelodysplastic syndrome (MDS)/MPN, 4) MDS, 5) acute myeloid leukemia (AML) and related precursor neoplasms, and 6) acute leukemias of ambiguous lineage.
  • In MPNs without chronic myelogenous leukemia, the genetic marker of JAK2 V617F is added to the diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
  • MDS has the new subtype of refractory cytopenia with unilineage dysplasia composed of refractory anemia, refractory neutropenia and refractory thrombocytopenia.
  • 22) (p13; q13); RBM15-MKL1 are added to the subtype of AML with recurrent genetic abnormalities, and AML with gene mutations of NPM1 and CEBPA are also added as provisional entities of it.
  • The myeloid neoplasms of the 4th WHO classification are comprehensive and seem to be dynamic by incorporating the results of leukemia researches.
  • [MeSH-major] Leukemia, Myeloid / classification
  • [MeSH-minor] Eosinophilia. Humans. Leukemia, Myeloid, Acute / genetics. Myelodysplastic Syndromes / genetics. Myeloproliferative Disorders / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics. Receptor, Platelet-Derived Growth Factor beta / genetics. World Health Organization

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860179.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  • [Number-of-references] 14
  •  go-up   go-down


90. Suzuki K, Adachi R, Hirayama A, Watanabe H, Otani S, Watanabe Y, Kasahara T: Indirubin, a Chinese anti-leukaemia drug, promotes neutrophilic differentiation of human myelocytic leukaemia HL-60 cells. Br J Haematol; 2005 Sep;130(5):681-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indirubin, a Chinese anti-leukaemia drug, promotes neutrophilic differentiation of human myelocytic leukaemia HL-60 cells.
  • Indirubin, a purple vegetable dye, is a traditional Chinese medicine for myelocytic leukaemia.
  • When indirubin was present during the neutrophilic differentiation of human myelocytic leukaemia HL-60 cells, it augmented superoxide production triggered by opsonized zymosan (OZ) by the terminally differentiated HL-60 cells.
  • These results suggest that indirubin augments the neutrophilic differentiation of human myelocytic leukaemia HL-60 cells through inhibition of CDK2 and activation of PU.1.
  • [MeSH-major] Cyclin-Dependent Kinases / antagonists & inhibitors. Leukemia, Myeloid / pathology. Neutrophils / drug effects

  • Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115123.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD18; 0 / Indoles; 0 / Interleukin-8; 0 / Receptors, Granulocyte Colony-Stimulating Factor; 0 / Receptors, Interleukin-8A; 0 / Retinoblastoma Protein; 11062-77-4 / Superoxides; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 59880-97-6 / N-Formylmethionine Leucyl-Phenylalanine; EC 2.7.11.22 / Cyclin-Dependent Kinases; V86L8P74GI / indirubin; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


91. Xue ZK, Jin J, Chen ZM, Lou JY, Yu YB: [Cytogenetic analysis on 135 cases of chronic myelogenous leukemias with non-simple Philadelphia chromosome]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct;16(5):997-1001
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytogenetic analysis on 135 cases of chronic myelogenous leukemias with non-simple Philadelphia chromosome].
  • The purpose of this study was to investigate 135 cases of chronic myelogenous leukemia with non-simple Philadelphia chromosome and to analyze their cytogenetic date.
  • The results showed that the overall frequency of chronic myelogenous leukemia with non-simple Philadelphia chromosome (based on 1210 cases of chromosome detection in chronic myelogenous leukemia) was 11.16%, which included 87 cases of chronic phase, 21 cases of accelerated phase and 27 cases of blastic phase.
  • It is concluded that karyotype analysis is helpful in diagnosis, prognosis, pathogenesis and treatment selection for chronic myelogenous leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18928582.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


92. Pulte D, Gondos A, Brenner H: Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004. J Natl Cancer Inst; 2008 Sep 17;100(18):1301-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004.
  • METHODS: We used period analysis to assess trends in 5- and 10-year survival in US patients younger than 15 years of age at diagnosis with four hematologic malignancies--acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma--over three recent 5-year intervals, 1990-1994, 1995-1999, and 2000-2004, using data on a total of 6957 patients from the Surveillance, Epidemiology, and End Results database.
  • RESULTS: Major improvements in 5- and 10-year relative survival between 1990-1994 and 2000-2004 were seen for acute lymphoblastic leukemia (from 80.2% to 87.5% and from 73.4% to 83.8%, respectively), acute non-lymphoblastic leukemia (from 41.9% to 59.9% and from 38.7% to 59.1%, respectively), and non-Hodgkin lymphoma (from 76.6% to 87.7% and from 73.0% to 86.9%, respectively).
  • Projected 10-year survival rates for children diagnosed in the 2005-2009 period were 88.0% for acute lymphoblastic leukemia, 63.9% for acute non-lymphoblastic leukemia, 90.6% for non-Hodgkin lymphoma, and 94.3% for Hodgkin lymphoma.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Hodgkin Disease / mortality. Humans. Leukemia, Myeloid, Acute / mortality. Lymphoma, Non-Hodgkin / mortality. Male. Mortality / trends. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Registries. Retrospective Studies. SEER Program. Survival Rate. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2008 Sep 17;100(18):1271-3 [18780861.001]
  • (PMID = 18780868.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


93. Koseki M, Asada N, Uryu H, Takeuchi M, Asakura H, Matsue K: Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. Int J Hematol; 2007 Dec;86(5):403-6
Hazardous Substances Data Bank. HEPARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis.
  • The current therapeutic strategy for disseminated intravascular coagulation (DIC) is limited to control of the underlying disease, and methods for the effective management of DIC have not been established.
  • A 35-year-old man who had undergone allogeneic bone marrow transplantation for chronic myelogenous leukemia was referred for relapse of his leukemia.
  • Although the disappearance of leukemic cells and a decrease in the BCR/ABL fusion gene were observed, he developed massive bleeding from the sigmoid colon after defecation.
  • A laboratory diagnosis of DIC with prominent fibrinolysis was based on elevated levels of both plasmin-alpha2-plasmin inhibitor complex and thrombin-antithrombin III complex.
  • [MeSH-major] Antifibrinolytic Agents / administration & dosage. Blast Crisis / complications. Colonic Diseases / drug therapy. Disseminated Intravascular Coagulation / drug therapy. Gastrointestinal Hemorrhage / drug therapy. Heparin / administration & dosage. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications. Tranexamic Acid / administration & dosage
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Agents / administration & dosage. Antithrombin III / analysis. Benzamides. Blood Transfusion. Bone Marrow Transplantation. Colon / pathology. Fibrinolysin / analysis. Genes, abl. Humans. Imatinib Mesylate. Male. Peptide Hydrolases / analysis. Piperazines / administration & dosage. Pyrimidines / administration & dosage. Shock / blood. Shock / etiology. Shock / pathology. Shock / therapy. Transplantation, Homologous. alpha-2-Antiplasmin / analysis

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18192107.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifibrinolytic Agents; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / alpha-2-Antiplasmin; 0 / antithrombin III-protease complex; 0 / plasmin-plasmin inhibitor complex; 6T84R30KC1 / Tranexamic Acid; 8A1O1M485B / Imatinib Mesylate; 9000-94-6 / Antithrombin III; 9005-49-6 / Heparin; EC 3.4.- / Peptide Hydrolases; EC 3.4.21.7 / Fibrinolysin
  •  go-up   go-down


94. Faller BA, Robu VG, Borghaei H: Therapy-related acute myelogenous leukemia with an 11q23/MLL translocation following adjuvant cisplatin and vinorelbine for non-small-cell lung cancer. Clin Lung Cancer; 2009 Nov;10(6):438-40
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myelogenous leukemia with an 11q23/MLL translocation following adjuvant cisplatin and vinorelbine for non-small-cell lung cancer.
  • Cisplatin-based chemotherapy has become an accepted standard in the adjuvant treatment of non-small-cell lung cancer (NSCLC).
  • We present a case of acute myelogenous leukemia with an 11q23/MLL rearrangement diagnosed 1 year after the completion of 4 cycles of cisplatin and vinorelbine for resected NSCLC.
  • To our knowledge, this is the first case of therapy-related acute myelogenous leukemia (t-AML) associated with this chemotherapy combination.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Translocation, Genetic / drug effects
  • [MeSH-minor] Aged. Carcinoma, Non-Small-Cell Lung / drug therapy. Chromosomes, Human, Pair 11. Cisplatin / administration & dosage. Follow-Up Studies. Histone-Lysine N-Methyltransferase. Humans. Lung Neoplasms / drug therapy. Male. Myeloid-Lymphoid Leukemia Protein / genetics. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives


95. Koh TT, Colby TV, Müller NL: Myeloid leukemias and lung involvement. Semin Respir Crit Care Med; 2005 Oct;26(5):514-9
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid leukemias and lung involvement.
  • Myeloid leukemias are clonal malignancies characterized by the presence of increased numbers of immature myeloid cells in the marrow and peripheral blood.
  • Pulmonary involvement by myeloid leukemia is relatively uncommon and seen mainly in patients with severe disease.
  • The most common form of pulmonary involvement consists of leukemic infiltration along the lymphatics in the peribronchovascular, septal, and pleural interstitial tissue.
  • Less common manifestations include myeloid sarcoma, leukostasis, leukemic cell lysis pneumopathy, and hyperleukocytic reaction.
  • The radiological manifestations of pulmonary leukemic cell infiltration and leukostasis consist mainly of bilateral thickening of the peribronchovascular interstitium and interlobular septa, a pattern that resembles that of interstitial pulmonary edema.
  • The radiological manifestations of leukemic cell lysis pneumopathy and hyperleukocytic reaction consist of symmetric bilateral areas of consolidation.
  • This manuscript reviews the histological and radiological intrathoracic manifestations of myelogenous leukemias.
  • [MeSH-major] Leukemia, Myeloid / radiography. Lung Diseases / radiography
  • [MeSH-minor] Diagnosis, Differential. Humans. Leukemic Infiltration / pathology. Leukemic Infiltration / radiography. Leukostasis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16267702.001).
  • [ISSN] 1069-3424
  • [Journal-full-title] Seminars in respiratory and critical care medicine
  • [ISO-abbreviation] Semin Respir Crit Care Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


96. Takeshita A, Shinjo K: [Biological markers for diagnosis of myeloid leukemia]. Nihon Rinsho; 2009 Oct;67(10):1916-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biological markers for diagnosis of myeloid leukemia].
  • There are several important biological markers in myeloid leukemia.
  • When we monitor the treatment of leukemia, WT1 is considered to be an important marker, and has been applied to immune therapy.
  • The abnormality of the genes of FLT3 and expression of P-gp are poor prognostic factors, and their inhibitors are developed in progress.
  • The surface antigen analysis of blast cells is also used in the classification and the treatment strategy decision.
  • Recently, as for the treatment of leukemia, stratification by various kinds of factors has been adopted in many prospective studies.
  • [MeSH-major] Biomarkers, Tumor / analysis. Leukemia, Myeloid / diagnosis. Leukemia, Myeloid / genetics. WT1 Proteins / analysis. fms-Like Tyrosine Kinase 3 / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860190.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycophorin; 0 / P-Glycoprotein; 0 / WT1 Proteins; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Number-of-references] 17
  •  go-up   go-down


97. Ramamoorthy SK, Pandita R, Prakash A, Ramaswamy NV, Al Bahar S: Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice. Acta Haematol; 2007;118(3):141-5
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice.
  • Acute leukemia presenting as cholestatic jaundice is rare.
  • It can occur due to granulocytic sarcoma compressing the bile ducts in case of acute myeloid leukemia.
  • Rarely, diffuse infiltration of the liver sinusoids by the leukemic blasts can present as cholestatic jaundice.
  • We report a case of chronic myeloid leukemia in lymphoid blast cell crisis presenting with severe cholestatic jaundice due to diffuse infiltration of the liver sinusoids with lymphoblasts.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Blast Crisis / drug therapy. Jaundice, Obstructive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Liver Neoplasms / drug therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Benzamides. Diagnosis, Differential. Drug-Related Side Effects and Adverse Reactions. Humans. Imatinib Mesylate. Male


98. Aşkin U, Durdu M, Senel E: Generalized granuloma annulare in a patient with myelocytic leukemia and chronic hepatitis B virus infection. Indian J Dermatol Venereol Leprol; 2009 May-Jun;75(3):287-9
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generalized granuloma annulare in a patient with myelocytic leukemia and chronic hepatitis B virus infection.
  • Granuloma annulare is a granulomatous disorder of the dermis and subcutaneous tissue, with different clinical types.
  • She had a history of myelocytic leukemia and chronic hepatitis B virus infection.
  • To date, both acute myelocytic leukemia and hepatitis B virus infection have been described independently in association with generalized granuloma annulare but have never been described together in association with generalized granuloma annulare.
  • [MeSH-major] Granuloma Annulare / diagnosis. Hepatitis B / diagnosis. Hepatitis B virus. Leukemia, Myeloid / diagnosis

  • Genetic Alliance. consumer health - Granuloma Annulare.
  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19439883.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


99. Tibes R, Kornblau SM, Qiu Y, Mousses SM, Robbins C, Moses T, Carpten JD: PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation. Br J Haematol; 2008 Feb;140(3):344-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation.
  • Despite its' central role, the precise mechanisms of the phosphoinositide 3-kinase/Akt (PI3K)/Akt pathway activation in acute myeloid leukaemia (AML) have not been elucidated.
  • Recently, a recurrent novel AKT1 pleckstrin homology domain (PHD) mutation leading to membrane translocation, constitutive AKT activation and leukaemia development in mice was described.
  • [MeSH-major] Blood Proteins / genetics. Leukemia, Myeloid, Acute / metabolism. Mutation. Phosphatidylinositol 3-Kinases / metabolism. Phosphoproteins / genetics. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction. src Homology Domains


100. Fritz J, Vogel W, Bares R, Horger M: Radiologic spectrum of extramedullary relapse of myelogenous leukemia in adults. AJR Am J Roentgenol; 2007 Jul;189(1):209-18
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiologic spectrum of extramedullary relapse of myelogenous leukemia in adults.
  • OBJECTIVE: Chloroma, also know as granulocytic sarcoma, is a localized extramedullary tumor composed of malignant cells of the myeloid cell line.
  • It occurs most frequently secondary to a history of myelogenous leukemia as extramedullary relapse.
  • The purpose of this article is to highlight the sites of involvement as well as the morphologic and imaging features of chloroma in patients with myelogenous leukemia.
  • CONCLUSION: Allogeneic stem cell transplantation now represents the treatment of choice for leukemia and for patients with leukemia relapse.
  • Because clinical and laboratory data are frequently not indicative, radiologic diagnosis of chloroma will become more important.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Sarcoma, Myeloid / diagnosis. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17579173.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down






Advertisement